Tag: Crohn’s disease

Since its introduction in 2003, a biologic has prevailed as the drug of choice in the treatment of Crohn’s disease. Its dominance for the past two decades is poorly supported by its limited therapeutic efficacy. In 2001, Infectious Diseases Incorporated entered a strategic alliance with the University of Florida...

In rare instances of Crohn’s disease, dietary modifications have produced what biologics and steroids haven’t yet shown to be possible: long-lasting remissions or cures. The quantitative availability of vitamins, minerals, and certain amino acids that are necessary for the immune system to operate at its best are compromised in...

 The present focus of Crohn’s disease treatment has been sclerosed for a long time. In 40% of cases, biologics cause brief remissions. They have yet to achieve long-term remissions. The FDA’s insistence on clinical validation through comparative, placebo-controlled, double-blinded trials has created a barrier to the acceptance of alternative...

Six Nigerians, consisting of 5 females and 1 male with confirmed inflammatory bowel disease (IBD) were recruited from a tertiary institution and two private hospitals in Lagos into this study from January 2001 to January 2014. Their ages at the time of first visit ranged from 27 to 65...

The association between chronic inflammatory disease and cancer has been well established through years of research. In corollary, progressive resistance to chimeric monoclonal antibodies has been reported in literature. The purpose of this investigation was to establish the overall trend of the chimeric monoclonal antibody (Infliximab) failure compared with...